Procept BioRobotics announces Aquablation Therapy received MIB from NICE

PROCEPT BioRobotics Corporation announced Aquablation Therapy received a MedTech Innovation Briefing, MIB, from the National Institute for Health Care Excellence, NICE, for benign prostate hyperplasia in the United Kingdom. NICE has recognized Aquablation Therapy is as effective as transurethral resection of the prostate, TURP, for the removal of prostate tissue for men with BPH. A panel of clinical experts said the technology is innovative compared to the standard of care and offers additional benefits, such as increased ability to preserve sexual function. "The NICE MedTech Innovation Briefing further validates the value we believe Aquablation Therapy brings to patients, doctors, hospitals and healthcare systems around the world," said Sham Shiblaq, Executive Vice President, Chief Commercial Officer of PROCEPT(R) BioRobotics. "The robust body of clinical evidence shows Aquablation therapy offers improved safety and durability when compared to transurethral resection of the prostate, which is the current gold standard surgical treatment option."